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AbsTrACT
The COVID-19 pandemic has led to an exponential 
increase in SARS- CoV-2 infections and associated deaths, 
and represents a significant challenge to healthcare 
professionals and facilities. Individual countries have 
taken several prevention and containment actions to 
control the spread of infection, including measures 
to guarantee safety of both healthcare professionals 
and patients who are at increased risk of infection 
from COVID-19. Faecal microbiota transplantation 
(FMT) has a well- established role in the treatment 
of Clostridioides difficile infection. In the time of the 
pandemic, FMT centres and stool banks are required 
to adopt a workflow that continues to ensure reliable 
patient access to FMT while maintaining safety and 
quality of procedures. In this position paper, based on the 
best available evidence, worldwide FMT experts provide 
guidance on issues relating to the impact of COVID-19 
on FMT, including patient selection, donor recruitment 
and selection, stool manufacturing, FMT procedures, 
patient follow- up and research activities.
InTroduCTIon
The outbreak of coronavirus disease 2019 
(COVID-19), caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS- CoV-2), was first 
identified in Wuhan and, despite the drastic safety 
measures taken by the Chinese government, rapidly 
evolved into a pandemic.
Consequently, healthcare facilities have inten-
sively decreased elective activities both to avoid 
potential transmission of the virus and to shift 
human and structural resources to the management 
of COVID-19. Beyond these general measures, 
some gastroenterological activities have been 
triaged according to risk and need, including endo-
scopic procedures, which result in aerosolisation of 
the virus.1 2 Therefore, several scientific societies 
have released recommendations to prioritise indi-
cations and implement safe working protocols of 
endoscopic clinical practice during the pandemic.3–5
In recent years faecal microbiota transplanta-
tion (FMT) has revolutionised the management of 
recurrent Clostridioides difficile infection (CDI).6 7 
As CDI continues to be associated with significant 
morbidity and mortality,8–11 FMT should be consid-
ered among the non- postponable gastroenterolog-
ical procedures during the COVID-19 pandemic, 
at least in high- risk patients with CDI where FMT 
could be life- saving and the benefits outweigh the 
risks. FMT has become increasingly standardised 
and safe, and guidance on the general organisation 
and the criteria required to establish a stool bank has 
recently been released.12 However, this pandemic 
has raised several issues and concerns regarding the 
impact and risks of FMT related to SARS- CoV-2, 
as the risk of a medium- to long- term cohabitation 
with this pandemic is inevitable. Recently, the FDA 
has recommended that only FMT products gener-
ated from stool donated before 1 December 2019 
should be used until proper SARS- CoV-2 testing 
of donors and/or stool 'as feasible' and screening 
protocols become available,13 and some FMT 
centres have suspended the active recruitment of 
new donors until FMT protocols are able to screen 
donors for COVID-19 and specific stool testing is 
available.14
Therefore, we aim to provide guidance regarding 
the reorganisation of FMT services in light of the 
evolving COVID-19 pandemic to assure the highest 
level of safety for the patients and healthcare 
providers who perform FMT.
MeThods
The main topics of this position paper were proposed 
by two authors (GI and GC) and reviewed and 
refined by the working group, who were selected as 
being internationally acknowledged experts in FMT 
and stool banking. To update and extend on previ-
ously published guidelines in light of the evolving 
COVID-19 pandemic,12 15 the following key topics 
were identified by GI and GC and approved by all 
authors: patient selection; donor recruitment and 
selection; stool manufacturing and supply; FMT 
procedure and follow- up of treated patients. In 
addition to pragmatic expert guidance, a litera-
ture review was conducted to capture best avail-
able current evidence. Recommendations from the 
major international medical institutions (eg, WHO, 
European and US Centers for Disease Prevention 
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Figure 1 Proposed treatment algorithm for patients with recurrent or refractory Clostridioides difficile infection (CDI) during the COVID-19 
pandemic. FMT, faecal microbiota transplantation.
and Control) and from scientific societies involved in digestive 
disorders were also reviewed.
However, in view of the limited evidence and need for urgent 
guidance, a formal standard consensus methodology was not 
followed.12 15 The first draft of the paper was primarily written 
by a small task force (GC, GI, CRK, BHM and ZK), and itera-
tive changes were made via virtual discussion among all experts, 
including three rounds of revision, until consensus was reached. 
The final position paper was approved by all experts after further 
virtual discussion.
PATIenT seleCTIon
recipients of FMT for recurrent/refractory CdI
The COVID-19 pandemic is going to affect the placement of FMT 
within the treatment algorithm for patients with recurrent or 
refractory CDI (figure 1).
CDI is present when it recurs within 8 weeks after the onset of 
a prior episode, provided that symptoms of the previous episode 
have been resolved after completion of initial treatment. Refrac-
tory disease occurs when CDI is unresponsive to the antimicrobial 
treatment and there is persistence of diarrhoea with positive C. 
difficile toxin, or of diarrhoea without toxin in the absence of other 
plausible causes of diarrhoea.16
The indication for FMT should be considered on a case- by- case 
basis, taking into account factors including: number and severity 
of previous CDI episodes; prior treatment modalities adminis-
tered and alternative possible strategies; comorbidities; and the 
safety, feasibility and practicality of FMT administration, given the 
specific complexities presented by the COVID-19 pandemic.
At present, it may be pragmatic to consider treating many 
‘typical’ recurrent CDI patients—who would have received FMT in 
the pre- COVID-19 era—with other approved therapies, including 
vancomycin, fidaxomicin and/or bezlotoxumab.16 17 Specifically, 
there may be a role for tapered and pulsed vancomycin regimens 
or extended fidaxomicin, although there is a paucity of data.17 
This strategy may have the dual benefit of effectively treating a 
patient with recurrent CDI, while also creating a ‘window’ of time 
in which clinical developments may occur which could facilitate 
safer administration of FMT—for example, improvements in 
donor screening techniques or adequate organisation of the FMT 
centre.
However, during the COVID-19 pandemic there are still likely 
to be a number of patients with presumed recurrent/refractory CDI 
for whom FMT is thought to be the most appropriate therapy—for 
example, especially those with fulminant CDI who have limited 
therapeutic alternatives and are felt to not be surgical candidates. 
In all such cases, careful evaluation of diagnostic certainty of CDI 
causing symptoms needs to be made prior to considering FMT.
Furthermore, it would be appropriate to have a detailed discus-
sion during the consent process with such patients to explain the 
complexities and uncertainties associated with FMT, and alter-
native treatment options during the pandemic. A further uncer-
tainty relates to the number of FMTs that may be appropriate in a 
CDI treatment regimen. Specifically, protocols related to pseudo-
membranous colitis have reported good outcomes either through 
repeating FMT every 3 days until pseudomembrane resolution18 
or, alternatively, giving 5 days of vancomycin in the case of FMT 
failure before a subsequent FMT.19 Almost all FMT studies in CDI 
and clinical guidelines recognise that sequential FMT has higher 
efficacy than a single infusion, at least in specific situations such 
as severe CDI or enema infusion.6 15 20 Therefore, when clinicians 
are committing to FMT as a treatment approach in the time of 
COVID-19, it seems reasonable that they are prepared to offer at 
least a second FMT to a patient in the event of initial FMT failure, 
using, if possible, aliquots from the same donor of the first infusion 
to reduce the risk for transmission. However, recognising the risks 
inherent in FMT administration at present, as well as the limited 
FMT stocks available for the forseeable future, stool banks and/or 
clinicians should consider on a case- by- case basis whether offering 
two or more FMTs for a patient with recurrent/refractory CDI 
is feasible, safe, appropriate and equitable compared with other 
patients who may also be in need.
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Yes
No
Swab or IgM positive
Negative
Yes/positive
Clinical evaluation of potential donors:
Potential exposure to, clinical picture suggestive of, or known diagnosis of, COVID-19? 
Other issues at the standard questionnaire?
Laboratory testing
Standard blood and stool exams
Nasopharynge l swab and serology for SARS-CoV2
Donation: 
Potential exposure to, clinical picture suggestive of, or known diagnosis of, COVID-19? 
Other issues at the standard questionnaire? 
Rapid stool assay for common pathogens and SARS-CoV-2 (advocated)
Donation discarded
Donor excluded
Donation ready for clinical use if rapid stool assay
performed
Stool storage
and quarantine
No/negative
After 8-12 weeks
Repeat of complete donor screening
(including nasopharyngeal swab and serology for 
SARS-CoV-2, without IgG if already positive) Positive
Donation ready for clinical use
Negative
Negative
Questionnaire and direct stool testing
for SARS-CoV2 after 30 daysIgG positive
Positive
Negative
After 8 weeks
Figure 2 Proposed workflow of stool donation during the COVID-19 pandemic.
When FMT is being considered in a COVID-19- positive patient 
with CDI, an additional consideration to the above should be 
whether the FMT procedure can be postponed. The treatment 
for recurrent/refractory CDI should be considered on a case- by- 
case basis, taking into account all the above discussed factors and 
also the COVID-19- related clinical picture. In such cases, a thor-
ough multidisciplinary discussion among FMT experts, infectious 
disease physicians and intensivists/anaesthetists is mandatory.
donor reCruITMenT And sCreenInG
To minimise the risk of COVID-19 infection of donors and 
recipients, we suggest specific changes in the pathway for donor 
recruitment and screening, principally including the evaluation 
of clinical history, laboratory testing and checks on the day of 
donation. For hospital- based stool banks, donors should also 
sign an informed consent, or at least be thoroughly informed by 
the physicians (according to local rules) to accept the potential 
risk of being infected with COVID-19 when they come to the 
hospital for testing and donation.21
The suggestions below are similar to those already released by 
some regulatory institutions (eg, the US Food and Drug Admin-
istration22 and the Italian National Transplant Centre23) and 
differ slightly from those previously released by our group.24 
Such measures should be adapted to local healthcare systems and 
updated accordingly with further evidence on COVID-19.
Questionnaire and clinical history
Although the initial clinical assessment and questionnaire 
administration are usually carried out in the FMT centres, in 
the COVID-19 era they can be generally implemented via tele-
medicine to avoid unnecessary exposure of potential donors 
to the hospital. The donor health questionnaire should be sent 
earlier to the candidate donor electronically, and the interview 
can be conducted through a video/phone consultation. For 
hospital- based stool banks, healthcare visits should be kept only 
on a case- to- case scenario, based on the physician's discretion (eg, 
clinical issues, technical obstacles, need for a cultural- linguistic 
mediator) or on donor desire for healthcare visit (eg, impossi-
bility for a confidential interview in a reserved space at home).
Additional items should be included in the clinical question-
naire. First, physicians should specifically assess if the donor has 
been diagnosed with laboratory- confirmed SARS- CoV-2 infec-
tion or has been closely exposed to subjects with suspected or 
proven infection.
In addition, potential donors should be clinically assessed for 
COVID-19 including, as suggested by the Center for Disease 
Control and Prevention (CDC)25: fever, cough, dyspnoea, chills, 
anosmia or ageusia, sore throat, muscle pain not explainable by 
alternative diagnosis within the previous 30 days.26 If the poten-
tial donor has any symptoms suggestive of COVID-19, he/she 
should be temporarily excluded from the next stage of the labo-
ratory screening and donation process. Moreover, healthcare 
workers actively involved in the management of patients should 
be excluded too.
laboratory testing
All donors who pass the questionnaire should undergo labo-
ratory examinations.12 Specific testing for the detection of 
SARS- CoV-2 must be added to the standard panel of donor 
laboratory testing,12 including at least nasopharyngeal swab 
and reverse transcription polymerase chain reaction (RT- PCR) 
assay and serology.27 Where available, validated molecular stool 
testing should be performed on the donated material (figure 2), 
and efforts from centres to include it in the donor screening are 
strongly advocated. All subjects who test positive must be tempo-
rarily excluded from donation, and advised of the result and to 
take precautionary measures against transmission, based on local 
protocols.
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2020-321829 on 3 July 2020. Downloaded from 
1558 Ianiro G, et al. Gut 2020;69:1555–1563. doi:10.1136/gutjnl-2020-321829
Guidelines
Table 1 Studies evaluating the presence of SARS- CoV-2 in faecal samples or anal/rectal swabs
First author Country no of patients
no of samples positive for sArs- 
CoV-2 Follow- up Culture
To et al28 China 15 4 (27%) rectal swabs None No
Xiao et al32 China 73 39 (53%) faecal samples 17 (24%) samples positive for a longer time 
than respiratory samples
No
Zhang et al34 China 15 4 (27%) anal swabs 6 (37%) swabs positive at day 5 No
Wölfel et al35 Germany 9 8 (88%) faecal samples 4 (36%) samples positive at day 20 Culture of viable virus failed
Wu et al36 China 74 41 (55%) faecal samples Samples positive for a mean of 28 days No
Wang et al37 China 153 44 (29%) faecal samples None 2 of 4 faeces samples positive by 
culture
Zhang et al38 China 7 6 (86%) rectal swabs Swabs positive for 5–23 days No
Zang et al39 China 5 3 (60%) faecal samples None Culture of viable virus failed
Some considerations about COVID-19 testing are necessary. 
First, there is no diagnostic testing so far that guarantees full 
accuracy of the diagnosis of COVID-19, nor can a single testing 
be used for all stages of the disease, so the examinations should 
be combined at different time points of the donor screening. 
Moreover, there is only limited evidence on COVID-19 diagnos-
tics, so our suggestions could be updated once more consolidated 
data are available. These diagnostic limits should be discussed 
with the recipient.
So far, the nasopharyngeal swab is the most commonly used 
test for diagnosis of pulmonary COVID-19. Viral RNA in the 
nasopharyngeal swab is detectable from a few days before start 
of the symptoms, peaks within the first week of symptom onset, 
and starts to decline by week 3, becoming subsequently undetect-
able.27 Serological diagnosis is especially important to intercept 
subjects with few or late symptoms where the nasopharyngeal 
swab could be less sensitive.
IgM and IgG ELISA have been found to be positive from day 
4 after symptom onset, with a peak after 2–3 weeks from the 
start of the infection28 29; specifically, IgM lowers at week 5 and 
disappears from week 7 of the illness, while IgG persists beyond 
week 7.30
Combined nasopharyngeal swab and IgM testing have been 
shown to increase diagnostic accuracy, so we recommend using 
them together to screen donors.31 However, the long- term 
persistence of antibodies remains unknown.
The screening of donor stools through a molecular test for 
SARS- CoV-2 has been advocated as the safest way forward to 
prevent the potential risk of viral transmission.14 However, 
although there is recent evidence that SARS- CoV-2 can be found 
in faeces32 and that it actively infects human gut enterocytes,33 it 
is not yet clear if the presence of faecal viral particles indicates 
infectivity, and if asymptomatic serologically positive individ-
uals can also shed the virus that way. Moreover, several studies 
report on longer faecal excretion than nasopharyngeal route 
(table 1).28 32 34–39 Recently, local protocols for stool SARS- CoV-2 
viral quantification have become available, and quantification 
has yielded promising results.40
Based on these considerations, positivity of PCR on naso-
pharyngeal swab/stool and/or IgM serology should be absolute 
criteria for exclusion from donation for at least 8 weeks; after 
that time frame, the potential donor could be considered again 
and re- tested. In case of IgG seroconversion for SARS- CoV-2, a 
donor should be excluded for 30 days and then re- tested with 
questionnaire and molecular stool testing; thereafter, if negative 
for stool testing and symptom- free, the donor should be allowed 
to donate.
Finally, as the COVID-19 diagnostics are still evolving, these 
suggestions should be updated as soon as further evidence is 
gained and new tests (eg, those on saliva) are developed.
donation workflow and quarantine
The donation workflow is summarised in figure 2. Poten-
tial donors who pass the questionnaire and laboratory testing 
described above can start providing faecal material. A dedicated 
toilet at the stool bank should be reserved for stool collection, 
and high- touch surface areas should be cleaned after each dona-
tion. If not operationally possible, stool should be collected at 
home with standard recommendations.12
At each donation, donors should be checked, beyond the 
standardised questionnaire already suggested,12 for: diagnosis 
of SARS- CoV-2 infection; household exposure to subjects with 
suspected or proven infections; clinical symptoms of COVID-19 
(as described above) not explainable by alternative diagnosis, 
since the last donation. Donors who prove to be positive for 
one of these items must be excluded from donation and previ-
ously donated stool, up to 4 weeks before the occurrence of 
symptoms/COVID-19 diagnosis, should be discarded as initial 
evidence suggests that SARS- CoV-2 is able to remain in stools up 
to 4 weeks after infection.36
For each donor, donated stools must be either: (1) immedi-
ately manufactured into FMT preparations, frozen and stored 
at −80°C, and finally quarantined until that donor has passed a 
further donor screening (to be repeated every 8–12 weeks) at the 
end of a period of donation, and be available for administration 
to patients only after this further check; or (2) assessed directly 
with validated molecular stool testing for common pathogens 
and for SARS- CoV-2. In this case, if direct testing is negative, 
they can be released for use without the need for quarantine, as 
recommended in our previous guidelines.12
sTool MAnuFACTurInG
Broadly, there are two models for preparing FMT: patient- 
selected fresh FMT or frozen FMT manufactured by a stool 
bank from healthy donors. However, due to factors related to 
safety, access and economics, the frozen FMT model manufac-
tured by stool banks is widely adopted by clinicians.41 42
Although rare clinical scenarios may require the use of fresh 
FMT prior to COVID-19, to date the fresh FMT model should 
be avoided to facilitate close adherence to recommended safety 
measures during the COVID-19 pandemic.43 Although the 
infectivity of RNA- positive SARS- CoV-2 stool is unknown, 
preliminary data suggest that viral shedding in the stool 
takes approximately 2–4 weeks,36 gastrointestinal symptoms 
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2020-321829 on 3 July 2020. Downloaded from 
1559Ianiro G, et al. Gut 2020;69:1555–1563. doi:10.1136/gutjnl-2020-321829
Guidelines
commonly precede respiratory symptoms,44 and viral shed-
ding in stool may lag behind despite clearance in respiratory 
samples.32 36
These data confirm the need for best practices in the manufac-
turing of FMT preparations. In our previous consensus report 
we recommended high- quality microbiology facilities (at least 
biosafety level 2) with robust standard operating procedures that 
allow safe processing of human samples by trained staff.12 Addi-
tionally, appropriate documentation, robust quality processes, 
retention of donor samples for further checks and standards for 
release of the final product are recommended.12 13 45 46 Therefore, 
as high safety measures were already recommended by previous 
guidelines,12 no significant changes in the stool manufacturing 
working protocol are currently needed to deal adequately with 
COVID-19.
FMT ProCedure And Follow-uP
routes of FMT delivery: which is best during CoVId-19?
Endoscopic FMT routes are most commonly used worldwide. 
Overall, endoscopic procedures have the potential to facilitate 
the transmission of virus to healthcare workers and patients (due 
to the close distance between patients and physicians, exposure 
to splashes, mucus or saliva during upper endoscopy, potential 
oral–faecal transmission during lower endoscopy, or by creating 
aerosol), although early real- world data suggest that the risk of 
viral transmission through endoscopy may be low.47 48
For these reasons it is prudent to create a process by which 
risks are minimised. Professional societies have released guide-
lines on gastrointestinal endoscopy and the use of personal 
protective equiptment (PPE) for these procedures in the setting 
of COVID-19.3 5 When FMT is administered via colonoscopy, 
it is recommended that the strict procedures to minimise risk 
before, during and after the procedure be followed (detailed in 
the section below). The only method of FMT delivery which 
does not generate aerosol is the ingestion of encapsulated donor 
stool. This is the preferred method, when available, to minimise 
transmission risks and usage of PPE which may be in limited 
supply. However, we acknowledge that capsulised FMT is still 
not widely available for use at all centres.
Delivery by retention enema would be less likely to be 
aerosol generating and can be performed by a single healthcare 
provider, minimising their exposure and PPE utilisation, but 
efficacy appears lower than endoscopic administration6 and 
patients may need multiple treatment courses, which would 
increase their exposure to the healthcare environment. FMT 
via nasoenteric or colonic transendoscopic enteral tube is used 
widely in some centres, particularly in elderly hospitalised 
patients. The otolaryngology literature considers procedures of 
the head and neck to be high risk in patients with confirmed 
or suspected COVID-19.49 The nose and nasopharyx have 
been shown to be reservoirs of high concentrations of the 
SARS- CoV-2 virus,50 and placement of the tube through the 
nasopharynx could cause particles to become aerosolised. 
Adequate topical analgesia to make the procedure comfortable 
for the patient and minimise coughing, gagging and sneezing is 
recommended. Furthermore, staff numbers present should be 
minimised. Those present should wear full PPE, including N95 
masks and face shields/goggles, gloves, hair nets, and dedicated 
operating room or procedural areas, ideally with negative pres-
sure, are advised.
Generally, it is advisable that FMT centres determine preferred 
routes of delivery on a case- by- case basis and according to their 
expertise in one or another route.
endoscopic procedures
Several scientific societies have issued recommendations for 
healthcare facilities providing elective procedures.4 5 51 Restric-
tions will vary based on country or state, and local consider-
ations should be identified and followed. When FMT is being 
performed in an endoscopy unit, the following procedures are 
advisable to minimise risk to staff and other patients.
Patient triage: Patients scheduled for outpatient elective endo-
scopic FMT should have temperature checked and be ques-
tioned about symptoms including fever, cough, dyspnoea, chills, 
anosmia or ageusia, sore throat and muscle pain on arrival for 
the procedure and prior to entering the facility. In patients who 
are suspected of, or have a known diagnosis of COVID-19, the 
physician should assess if the procedure is postponable based on 
the clinical picture of the patient and, in case, he/she should be 
instructed to perform a nasopharyngeal swab and to resume oral 
vancomycin to prevent recurrence.
The outcome of these checks must be tracked in an appro-
priate register.
Patients who present with symptoms suggestive of COVID-19 
should be asked to contact their primary care provider for further 
evaluation. Patients should be given a cloth or surgical facemask 
to wear on arrival at the facility and strict social distancing 
should be maintained in waiting room areas, with chairs at least 
2 metres apart. Visitors/family members should be prohibited 
from remaining on site and can be telephoned afterwards to 
meet the patient at the door at time of discharge.
PPE: It is recommended that all patients, healthcare providers 
and staff wear surgical facemasks at all times. FMT procedures 
involving mucous membranes including nasoenteric tube inser-
tion, upper endoscopy or colonoscopy require N95 masks and 
face shields to be worn by proceduralists and any members of the 
healthcare team present. Staff should be educated on the proper 
methods for donning and removing PPE.
Recovery room: Patients should ideally recover in the room 
in which the procedure is conducted, which can then be termi-
nally cleaned before being used for the next patient. If space 
does not permit, then the patient should be recovered in an area 
in which social distancing can be maintained (at least 2 metres 
between patients). There is no sound basis for asking patients 
to retain donor material for longer than is necessary to recover 
from sedation.
Follow-up
Patients should be called 24 hours after the procedure to assess 
any short- term adverse events or procedural complications. 
Follow- up appointments should be conducted using telemedi-
cine as per institutional protocols, when possible. Follow- up 
evaluations at different time points (between 1 and 8 weeks) 
are advisable to discuss post- FMT symptoms, assess for signs 
of recurrence and enquire about symptoms of infection.43 52 
Patients should be instructed to contact the provider immedi-
ately if symptoms of infection develop or if they are diagnosed 
with COVID-19 within 28 days of the procedure so that contact 
tracing and monitoring of exposed staff can be performed, as 
well as 'look- back' testing of retained donor stool samples. If 
patients develop diarrhoea suggestive of CDI recurrence, they 
can be triaged by telephone to determine whether they need to 
seek care at the hospital or whether they can submit stool for 
testing and/or start empiric anti- CDI therapy at home. Those 
whose prior CDI episodes have been severe or who report diar-
rhoea suggestive of CDI recurrence together with high fevers, 
severe abdominal pain or vomiting should be evaluated in an 
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Table 2 Summary of recommendations
Outpatient evaluation  ► Remote assessment (medical interview by voice or video call)
 ► If remote assessment not possible: Checkpoint at entrance (body temperature; patients must wear surgical mask; hand wash; no company 
admitted)
 ► COVID-19 screening (exposure and medical history, symptoms, laboratory analyses)
 ► If clinical suspect of COVID-19, nasopharyngeal swab must be performed
Inpatient evaluation  ► Exclude COVID-19 (nasopharyngeal swab, laboratory exams, if fever or respiratory distress perform chest CT scan)
 ► Isolation (contact precautions and droplets in air); visitors not admitted
 ► If patients positive for COVID-19:
 – Dedicated COVID-19 wards and dedicated healthcare professionals
 – Dedicated radiology and invasive procedures
 – Evaluate the risk of complications or infective issues compared with the benefit of FMT procedure
Donor screening  ► Remote assessment (screening medical interview by voice or video call)
 ► COVID-19 screening (exposure to confirmed cases, medical history, symptoms)
 ► Laboratory examinations (standard blood and stool tests plus nasopharyngeal swab and serology for SARS- CoV-2)
Stool donation  ► Repeat standard and COVID-19 screening interview (preferably remote assessment prior to access to the clinic)
 ► Checkpoint at entrance (body temperature, subjects must wear surgical mask, hand wash, company forbidden)
 ► Direct stool testing for SARS- CoV-2 and/or common pathogens; quarantine approach as potential alternative
Stool handling  ► Stool transferred to microbiological laboratory by dedicated health workers
 ► Retention of stool samples for 'look- back' testing is recommended
 ► Stool processing conforms to local standard operating procedures and biosafety protocols; at minimum, biosafety level 2 is advised
FMT by endoscopic procedure  ► Access to the endoscopy service:
 – Differentiate logistic pathways of patient access according to COVID-19 diagnosis
 – Outpatients can be accompanied by a caregiver
 – Checkpoint at entrance (body temperature, patients and caregiver must wear surgical mask, hand wash)
 ► Management of the endoscopic procedure:
 – Differentiate endoscopic and recovery room (dedicated rooms for COVID-19 patients)
 – Dedicated healthcare professionals for COVID-19
 – Staff present in the endoscopic room must be protected for drops in air (wear FFP2, protect eyes, wear double gloves, wear shields or hats)
 – Patients should wear surgical mask
 ► Discharge of the patient:
 – Keep differentiated logistic pathways according to COVID-19 diagnosis
 – Inpatient return to the ward accompanied by dedicated healthcare workers
 – Outpatient discharged after brief observation, medical and nurse staff report follow- up instructions to caregivers via remote contact
Follow- up Follow- up visits should preferably take place via remote assessment (medical interview by voice or video call, reports sent by email), outpatient 
visits should be limited to cases where in- presence assessment is mandatory
Research activities  ► Ongoing trials should adapt their protocols according to the changing status of COVID-19
 ► Upcoming trials should be designed taking into account the same security measures proposed in this document for clinical practice
 ► Virtual visits (especially those after treatment) should be considered rather than in- person assessments
 ► Donor recruitment protocols and workflows must follow international guidelines
 ► The use of multi- donor FMT should only be considered within a FMT trial if there is strict adherence to proposed security measures
 ► The use of frozen stools is preferred over fresh material, although SARS- CoV-2 can probably survive the storage conditions
 ► Highly safe environment (at least biosafety level 2) for stool manipulation
 ► Use of registers, application of the same strict traceability protocols already recommended for clinical practice
emergency room or physician's office. If the conditions and indi-
cation exist, further treatment with FMT may be considered.
reseArCh ACTIVITIes
The enormous potential impact of COVID-19 on many facets of 
research (including the undertaking of clinical trials) has already 
been recognised.53 54 This clearly applies to the very active field 
of FMT clinical trials. Specifically, prior to the COVID-19 
pandemic there were >300 trials involving FMT registered on 
www. clinicaltrials. gov, involving a myriad of indications from 
autism to ulcerative colitis.55–57 In the months leading up to the 
current pandemic there were two important safety alerts from the 
USA relating to the possible transfer of pathogens to patients via 
FMT, resulting in one death and five hospitalisations.13 58 Before 
those undertaking FMT research were able to fully respond to 
the last alert, the COVID-19 pandemic struck and FMT trial 
activity has been currently paused in most regions.
However, as the most realistic scenario is the medium to longer 
cohabitation with COVID-19, FMT- related research should take 
adequate security measures rather than being suspended, despite 
potential complexity.
To guarantee the best possible safety based on current 
evidence, ongoing trials should adapt their protocols according 
to the changing status of COVID-19, and upcoming trials should 
be designed taking into account the same security measures 
proposed in this document for clinical practice.
For specific patient populations, including those with inflam-
matory bowel disease (IBD) treated with immunosuppressive 
medication or cancer patients on chemotherapy, exposure to 
a healthcare facility for FMT administration may be difficult. 
For example, patients with IBD living in high prevalence areas 
for COVID-19 have been recommended to ‘shield’ from public 
activity by government- mandated advice and professional guide-
lines59 60 to minimise the risk of infection.
Additionally, the panel discussed solutions to keep a smooth 
patient recruitment in FMT clinical trials. To avoid enrolment 
hurdles and to safely perform follow- up, virtual visits (especially 
those after treatment) should be considered rather than in- person 
assessments.59 61 Moreover, where possible, potentially eligible 
candidates should be provided with specific documentation (eg, 
the ticket of the scheduled visit) to be able to reach the hospital 
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without being stopped by authorities if unnecessary movements 
are not allowed during the lockdown phase.
Furthermore, for FMT trials there should be a pragmatic 
ongoing dialogue between trial investigators and the ethical, 
funding and administrative bodies overseeing the study to ensure 
that studies can still proceed safely and effectively, although with 
potential adaptations; this may require flexibility in study proto-
cols, review of appropriate and achievable endpoints (eg, length 
of participant follow- up) and consideration of unblinding if 
required. To ensure the safety of patients, also taking into account 
recent FMT- related adverse events in the context of clinical 
trials,58 it is recommended that donor recruitment protocols and 
workflows follow international guidelines.12 The use of multi- 
donor FMT could potentially increase the risk of COVID-19 
transmission and should only be considered within a FMT trial 
if there is strict adherence to proposed security measures. The 
development of a reliable stool assay for SARS- CoV2 is also 
advocated to make the implementation of clinical trials faster 
and safer and, when available, such diagnostic tools should be 
included in the screening protocols.
As suggested for clinical practice, the use of frozen stools is 
preferred over fresh material, although SARS- CoV-2 can prob-
ably survive the storage conditions. The manipulation of faecal 
aliquots and the storage of stool samples before and after FMT 
should be done in a highly safe environment (at least biosafety 
level 2). Additionally, members of the FMT staff who are in 
charge of sample handling should undergo, in the COVID-19 
era, a more rigorous safety training as there is a potential risk of 
being exposed to SARS- CoV-2.
The use of registers and the application of the same strict 
traceability protocols that have been recommended for clinical 
practice are also recommended for research protocols.12
Finally, these principles for assessing SARS- CoV-2, designed 
for standard FMT, are also recommended to be applied to trials 
investigating next- generation microbiome drugs which are 
directly derived from human faeces (while it is not necessary for 
synthetically derived ones).
ConClusIons
The COVID-19 pandemic is challenging the healthcare systems 
of individual countries worldwide, and it is reasonable to assume 
that it will be present also in the near future, forcing us to adapt 
overall clinical- procedural standards. Therefore, we have learnt 
to rationalise medical care services with criteria dictated first 
by the emergency and then by reasoned planning, with varying 
degrees of difficulty in different clinical scenarios.
In that context, FMT finds its place as a life- saving proce-
dure for a considerable number of patients with CDI which, 
despite COVID-19, will continue to be numerous in clinical 
practice.
The general workflow of a FMT service, as recommended 
before the diffusion of COVID-19,12 already allows guaran-
teeing high levels of safety, both for physicians and for patients. 
Due to their robust organisation, FMT services can adapt to the 
pandemic- related scenario, and a few feasible security measures, 
which are described in this position paper (table 2) are advo-
cated to assure a safe cohabitation with COVID-19 in the near 
future. However, we recognise that certain recommendations 
here represent expert opinion rather than clear evidence- based 
practice and that, given the rapid developments occurring in 
evidence related to COVID-19 pathophysiology, they may need 
updating in the future to maintain the highest safety levels for 
FMT services.
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